CN111991383A - 苯乙酸前药的治疗性监测方法 - Google Patents

苯乙酸前药的治疗性监测方法 Download PDF

Info

Publication number
CN111991383A
CN111991383A CN202010449455.7A CN202010449455A CN111991383A CN 111991383 A CN111991383 A CN 111991383A CN 202010449455 A CN202010449455 A CN 202010449455A CN 111991383 A CN111991383 A CN 111991383A
Authority
CN
China
Prior art keywords
paa
dose
pagn
pagn ratio
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010449455.7A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·沙施米德
马苏德·默克塔拉你
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imeldica Pharmaceutical Co
Original Assignee
Imeldica Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111991383(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imeldica Pharmaceutical Co filed Critical Imeldica Pharmaceutical Co
Publication of CN111991383A publication Critical patent/CN111991383A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
CN202010449455.7A 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法 Pending CN111991383A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
US61/636,256 2012-04-20
CN201280074143.6A CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280074143.6A Division CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Publications (1)

Publication Number Publication Date
CN111991383A true CN111991383A (zh) 2020-11-27

Family

ID=49380684

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280074143.6A Pending CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法
CN202010449455.7A Pending CN111991383A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法
CN202111191403.5A Pending CN113995743A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201280074143.6A Pending CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111191403.5A Pending CN113995743A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Country Status (25)

Country Link
US (4) US9561197B2 (enExample)
EP (2) EP3222275B1 (enExample)
JP (3) JP6234436B2 (enExample)
KR (2) KR102264579B1 (enExample)
CN (3) CN104540507A (enExample)
AU (3) AU2012377389A1 (enExample)
BR (1) BR112014026138A2 (enExample)
CL (2) CL2014002807A1 (enExample)
CY (1) CY1118838T1 (enExample)
DK (1) DK2846791T3 (enExample)
EC (1) ECSP14024561A (enExample)
ES (2) ES2807951T3 (enExample)
HR (1) HRP20170651T1 (enExample)
HU (1) HUE032726T2 (enExample)
IL (2) IL235127A (enExample)
LT (1) LT2846791T (enExample)
MX (1) MX365302B (enExample)
PL (1) PL2846791T3 (enExample)
PT (1) PT2846791T (enExample)
RS (1) RS55870B1 (enExample)
SG (2) SG10201608749UA (enExample)
SI (1) SI2846791T1 (enExample)
SM (1) SMT201700219T1 (enExample)
WO (1) WO2013158145A1 (enExample)
ZA (1) ZA201407597B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107271696A (zh) 2011-09-30 2017-10-20 海波龙治疗有限责任公司 氮清除药物的治疗性监测方法
HUE032726T2 (en) 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
SI2922576T1 (en) 2012-11-21 2018-04-30 Horizon Therapeutics, Llc Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
WO2015057747A1 (en) 2013-10-14 2015-04-23 Hyperion Therapeutics, Inc. Methods of treating urea cycle disorders
EP3013372B1 (en) * 2014-06-04 2019-07-10 Immedica Pharma AB Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100008859A1 (en) * 2008-04-29 2010-01-14 Scharschmidt Bruce Methods of treatment using ammonia-scavenging drugs
AU2010247750A1 (en) * 2009-05-11 2011-12-15 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US20120022157A1 (en) * 2008-08-29 2012-01-26 Ucyclyd Pharma, Inc Dosing and monitoring patients on nitrogen-scavenging drugs

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0858441B1 (en) 1995-02-07 2001-05-09 Brusilow Enterprises, LLC Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
EP2237684A2 (en) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
PL2330892T3 (pl) * 2008-08-29 2017-05-31 Horizon Therapeutics, Llc Sposoby leczenia z zastosowaniem leków wychwytujących amoniak
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2012028620A1 (en) 2010-08-31 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
CN107271696A (zh) 2011-09-30 2017-10-20 海波龙治疗有限责任公司 氮清除药物的治疗性监测方法
HUE032726T2 (en) 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
SI2922576T1 (en) 2012-11-21 2018-04-30 Horizon Therapeutics, Llc Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100008859A1 (en) * 2008-04-29 2010-01-14 Scharschmidt Bruce Methods of treatment using ammonia-scavenging drugs
US20120022157A1 (en) * 2008-08-29 2012-01-26 Ucyclyd Pharma, Inc Dosing and monitoring patients on nitrogen-scavenging drugs
AU2010247750A1 (en) * 2009-05-11 2011-12-15 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRENDAN M. MCGUIRE ET AL: "Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis", HEPATOLOGY, vol. 51, no. 6, 30 June 2010 (2010-06-30), XP055171452, DOI: 10.1002/hep.23589 *

Also Published As

Publication number Publication date
MX365302B (es) 2019-05-29
MX2014012694A (es) 2015-06-03
WO2013158145A1 (en) 2013-10-24
JP2018039830A (ja) 2018-03-15
SG10201608749UA (en) 2016-12-29
US20180263938A1 (en) 2018-09-20
SMT201700219T1 (it) 2017-05-08
KR20150013170A (ko) 2015-02-04
ZA201407597B (en) 2017-05-31
ES2623470T3 (es) 2017-07-11
JP6637941B2 (ja) 2020-01-29
AU2018200163A1 (en) 2018-02-01
US20180015058A1 (en) 2018-01-18
ECSP14024561A (es) 2015-09-30
AU2018200163B2 (en) 2018-12-20
CL2014002807A1 (es) 2015-02-27
HRP20170651T1 (hr) 2017-06-30
PT2846791T (pt) 2017-05-25
PL2846791T3 (pl) 2017-07-31
CY1118838T1 (el) 2018-01-10
US20170266143A1 (en) 2017-09-21
JP2015514757A (ja) 2015-05-21
IL255918A (en) 2018-01-31
AU2019201811A1 (en) 2019-04-04
IL255918B (en) 2019-06-30
JP2019219413A (ja) 2019-12-26
CN104540507A (zh) 2015-04-22
WO2013158145A9 (en) 2014-05-01
EP3222275B1 (en) 2020-06-24
DK2846791T3 (en) 2017-03-27
HK1243959A1 (en) 2018-07-27
US20130281530A1 (en) 2013-10-24
RS55870B1 (sr) 2017-08-31
EP2846791B1 (en) 2017-02-08
IL235127A (en) 2017-12-31
CL2017001375A1 (es) 2018-01-05
SI2846791T1 (sl) 2017-06-30
AU2019201811B2 (en) 2020-07-09
AU2012377389A1 (en) 2014-10-30
BR112014026138A2 (pt) 2017-06-27
LT2846791T (lt) 2017-04-10
KR20190116552A (ko) 2019-10-14
JP6234436B2 (ja) 2017-11-22
HUE032726T2 (en) 2017-10-30
SG11201406745VA (en) 2014-12-30
KR102264579B1 (ko) 2021-06-11
ES2807951T3 (es) 2021-02-24
EP2846791A1 (en) 2015-03-18
EP2846791A4 (en) 2015-08-19
US9561197B2 (en) 2017-02-07
CN113995743A (zh) 2022-02-01
HK1208380A1 (en) 2016-03-04
EP3222275A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
AU2019201811B2 (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
US10183006B2 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
CN104797272A (zh) 施用及评价用于治疗肝性脑病的氮清除药物的方法
HK1243959B (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
HK1208380B (en) Hpn-100 for use in the treatment of nitrogen retention disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination